Earlier, it was reported that the Italian company Kedrion Biopharma would launch in the Tashkent region the production of a Factor VIII based coagulation medicinal specialty. However, the company representatives refuted the news regarding the upcoming construction of the plant.
“Kedrion Biopharma - an international biopharmaceutical company specializing in the collection and fractionation of human plasma for the production of plasma-derived medicines - wishes to clarify that it has not signed any agreement for the construction of said plant, and therefore has not started any of the required technology transfer activities,” the message reads.
According to company representative’s report, Kedrion Biopharma is nevertheless open to evaluating cooperation initiatives - with the government of Uzbekistan - that may lead to making its knowledge and skills in the sector available.
“Kedrion, in fact, is committed to sharing as much as possible its expertise, know-how and technologies, with the aim of promoting self-sufficiency in the provision of plasma-derived products among communities and healthcare systems all over the globe, and thereby contributing to improving the living conditions of those suffering from rare diseases,” noted in the report.
